GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $299,460.00 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 3,220 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total value of $299,460.00. Following the completion of the transaction, the chief executive officer directly owned 1,720 shares in the company, valued at approximately $159,960. This trade represents a 65.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, July 1st, Katherine Stueland sold 9,657 shares of GeneDx stock. The stock was sold at an average price of $90.94, for a total value of $878,207.58.
• On Tuesday, April 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $113.09, for a total value of $243,595.86.

GeneDx Price Performance

Shares of NASDAQ WGS traded down $4.35 during midday trading on Friday, reaching $82.56. 888,073 shares of the company were exchanged, compared to its average volume of 825,253. The stock's 50-day moving average price is $73.18 and its 200-day moving average price is $82.65. The stock has a market cap of $2.36 billion, a P/E ratio of -58.55 and a beta of 2.01. GeneDx Holdings Corp. has a one year low of $25.32 and a one year high of $117.75. The company has a quick ratio of 3.07, a current ratio of 3.25 and a debt-to-equity ratio of 0.20.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. GeneDx had a negative net margin of 11.69% and a positive return on equity of 10.17%. The company had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Guggenheim reissued a "buy" rating and issued a $115.00 price target (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Jefferies Financial Group upgraded GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a report on Friday, May 9th. TD Securities reduced their price objective on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Piper Sandler began coverage on shares of GeneDx in a research report on Wednesday. They set an "overweight" rating and a $110.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $92.33.

Institutional Trading of GeneDx

Several institutional investors have recently modified their holdings of the business. Harbor Capital Advisors Inc. grew its stake in shares of GeneDx by 150.9% in the second quarter. Harbor Capital Advisors Inc. now owns 39,979 shares of the company's stock worth $3,690,000 after purchasing an additional 24,042 shares during the last quarter. MRA Advisory Group bought a new stake in GeneDx during the second quarter valued at $298,000. Voya Investment Management LLC boosted its position in GeneDx by 79.5% during the first quarter. Voya Investment Management LLC now owns 6,819 shares of the company's stock valued at $604,000 after acquiring an additional 3,021 shares during the last quarter. Strs Ohio bought a new stake in GeneDx during the first quarter valued at $230,000. Finally, Ellsworth Advisors LLC bought a new stake in GeneDx during the first quarter valued at $1,414,000. Institutional investors own 61.72% of the company's stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.